CEL-SCI Q1 2024 Earnings Report $0.39 -0.01 (-2.21%) As of 04:00 PM Eastern Earnings History CEL-SCI EPS ResultsActual EPS-$0.14Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACEL-SCI Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACEL-SCI Announcement DetailsQuarterQ1 2024Date2/14/2024TimeN/AConference Call ResourcesCVM Earnings History CEL-SCI Earnings HeadlinesCEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.comJanuary 19 at 2:36 AM | americanbankingnews.comCEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck CancerJanuary 14, 2025 | finance.yahoo.comAAPL: Double Your Returns in 24 Hours?Trader Chris Pulver is diving deep into the inner workings of Wall Street... To reveal a trading method he’s kept under wraps for years. You see… Thanks to “liquidity levels” which show us Wall Street’s biggest undercover buy orders in real time… This method has shown the ability to DOUBLE our returns…January 21, 2025 | ProsperityPub (Ad)CEL-SCI (AMEX:CVM) Stock Quotes, Forecast and News SummaryDecember 31, 2024 | benzinga.comWhat's Going On With Cel-Sci Shares Premarket On Monday?December 30, 2024 | benzinga.comCEL-SCI prices $5M public offering at 31c per shareDecember 30, 2024 | markets.businessinsider.comSee More CEL-SCI Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CEL-SCI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CEL-SCI and other key companies, straight to your email. Email Address About CEL-SCICEL-SCI (NYSE:CVM), a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.View CEL-SCI ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
